SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that new data supporting its GBT440 program in sickle cell disease (SCD) will be presented at the 58 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. The poster presentations will include additional data from the ongoing Phase 1/2 GBT440-001 trial of GBT440 including dosing of 900 mg per day in SCD patients for up to 6 months, and the metabolism of GBT440 in healthy subjects. The poster presentations will also include the methodology utilized to develop the Patient Reported Outcome (PRO) tool that will be used in the HOPE ( Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polym Erization) Study. Patient enrollment of variant SCD genotypes in the GBT440-001 trial is ongoing, and will support the inclusion of patients with variant genotypes in the HOPE Study. GBT440 is being developed as an oral, once-daily therapy for patients with sickle cell disease (SCD). GBT440 works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes GBT440 blocks polymerization and the resultant sickling of red blood cells. With the potential to restore normal hemoglobin function and improve oxygen delivery, GBT believes that GBT440 may be capable of modifying the progression of SCD. The U.S. Food and Drug Administration (FDA) has granted GBT440 both fast track and orphan drug designations for the treatment of patients with SCD, in recognition of the critical need for new treatments. The pivotal HOPE Study will begin screening patients by December 2016.